Cargando…

New biologics and small molecules in inflammatory bowel disease: an update

Inflammatory bowel disease (IBD) is a spectrum of immune-mediated inflammatory disorders with a complex multifactorial pathogenesis, where different pathways may predominate in different individuals. This complexity will most likely require a panoply of drugs targeting different pathways if one want...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabino, João, Verstockt, Bram, Vermeire, Séverine, Ferrante, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537282/ https://www.ncbi.nlm.nih.gov/pubmed/31205488 http://dx.doi.org/10.1177/1756284819853208

Ejemplares similares

New treatment options for inflammatory bowel diseases
por: Verstockt, Bram, et al.
Publicado: (2018)

Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
por: Verstockt, Sare, et al.
Publicado: (2021)

Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis
por: Sudhakar, Padhmanand, et al.
Publicado: (2020)

Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
por: Alsoud, Dahham, et al.
Publicado: (2022)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Inflammatory Bowel Disease (IBD)—A Textbook Case for Multi-Centric Banking of Human Biological Materials
por: Cleynen, Isabelle, et al.
Publicado: (2019)

Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Integrated analysis of microbe-host interactions in Crohn’s disease reveals potential mechanisms of microbial proteins on host gene expression
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium
por: Creyns, Brecht, et al.
Publicado: (2020)

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases
por: Verstockt, Bram, et al.
Publicado: (2020)

Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease
por: Verstockt, Bram, et al.
Publicado: (2018)

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis
por: Lee, Ho-Su, et al.
Publicado: (2020)

Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
por: Jacobs, Inge, et al.
Publicado: (2021)

Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon
por: Verstockt, Bram, et al.
Publicado: (2020)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives
por: Wellens, Judith, et al.
Publicado: (2023)

Microbiota, not host origin drives ex vivo intestinal epithelial responses
por: Arnauts, Kaline, et al.
Publicado: (2022)

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer
por: Jauregui-Amezaga, Aranzazu, et al.
Publicado: (2016)

Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions
por: Sudhakar, Padhmanand, et al.
Publicado: (2021)

Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
por: Kantasiripitak, Wannee, et al.
Publicado: (2022)

Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways
por: Prins, Marileen M., et al.
Publicado: (2021)

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD
por: Dierckx, Tim, et al.
Publicado: (2019)

Vaccination and infection prevention in inflammatory bowel disease
por: Vermeire, Severine, et al.
Publicado: (2010)

Small Molecule Drugs in Inflammatory Bowel Diseases
por: Ben Ghezala, Inès, et al.
Publicado: (2021)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile
por: Bollen, Lize, et al.
Publicado: (2015)

Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
por: Cheah, Eric, et al.
Publicado: (2023)

Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
por: Katsanos, Konstantinos H., et al.
Publicado: (2017)

Let Food Be Thy Medicine—Its Role in Crohn’s Disease
por: Wellens, Judith, et al.
Publicado: (2021)

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study
por: Schoefs, Elise, et al.
Publicado: (2022)

Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease
por: Van den Berghe, Nathalie, et al.
Publicado: (2023)

JAK Inhibitors: Back to Small Molecules for the Treatment of IBD
por: Panés, Julian, et al.
Publicado: (2020)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
por: Pouillon, Lieven, et al.
Publicado: (2019)

Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease
por: Balderramo, Domingo
Publicado: (2022)

Big data in IBD: big progress for clinical practice
por: Seyed Tabib, Nasim Sadat, et al.
Publicado: (2020)

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
por: Na, Soo-Young, et al.
Publicado: (2022)

Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease
por: Bilal, Muhammad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_se432bbu1u0aga6tednkmd7cag